OKKO Health Selected as One of 11 Start-Ups on Bayer’s G4A Digital HealthPartnership Programme

19th October 2019

OKKO Health, a UK-based software company specialising in tele-ophthalmology, has

been accepted onto a Digital Health Partnership run by pharmaceutical giant Bayer. The start-up is the only UK based company to be accepted into this year’s cohort. Bayer’s

G4A Digital Health Partnership Program has been operating since 2012, selecting the

most promising start-ups from around the world which operate in Digital Health. This

year, 11 start-up companies were selected by Bayer, from over 750 applications out of

65 countries, based on the strategic fit, development stage of the project, and the

assessment of internal experts

OKKO Health is developing an app which uses the camera technology, already present

within modern smartphones, along with a specially designed video game, to enable

ophthalmology patients to monitor their eye health at home. As part of the G4A

program, start-ups will receive EUR 75.000 funding for co-creating products or

solutions, as well mentoring and coaching by Bayer executives.

“We received a high number of very mature digital health startup applications and are

excited to jointly develop and scale new digital solutions that will help benefit the health

of our patients and consumers,” said Eugene Borukhovich, Head of Digital Health at


Sophie Park, Chief Strategist for the G4A Partnerships team at Bayer Berlin, added

“What really stands out about OKKO Health is its ambition to dramatically evolve how

ophthalmology embraces technological advances. The potential for impact on both

patients and clinicians can only be positive.”

On joining the program, OKKO Health’s CEO, Dr Stephanie Campbell said “The

recognition of a global health company such as Bayer is a huge endorsement for us.

We’re looking forward to having their involvement accelerate our product development

and launching the first app in 2020.”

OKKO Health Press Kit


OKKO Health has developed smartphone software for accurate remote monitoring of

eye health outside of ophthalmology clinics. This hardware-free solution runs as a

simple video game app for ophthalmology patients to play at home, using the sensors

in the phone to accurately measure features of their vision. For patients, this means

that eye health can be tracked between in-person clinic visits, and ultimately will lead to

personalised and remote care. For eye specialists, this innovation brings viable tele-

health to the ophthalmology space. The company was founded by Dr Stephanie

Campbell, a senior NHS eye specialist and researcher. It has been backed by

pharmaceutical giant Bayer under its G4A Digital Health Partnerships programme and is

a member of Digital Health London’s Launchpad Programme. OKKO Health is the

trading name of Okulo Limited. It is headquartered in Bristol, UK.

About G4A

Bayer is combining the Group’s digital health initiatives under the name G4A (formerly

Grants4Apps). In addition to identifying new technologies, business models, and market

trends, these initiatives also involve collaborating with start-ups. Since its launch in

2013, Bayer has supported over 150 digital health companies. This has resulted in more

than 30 direct collaborations with digital health companies. Bayer now operates G4A in

more than 13 countries, developing and promoting collaborative health care projects

around the world.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health

care and nutrition. Its products and services are designed to benefit people by

supporting efforts to overcome the major challenges presented by a growing and aging

global population. At the same time, the Group aims to increase its earning power and

create value through innovation and growth. Bayer is committed to the principles of

sustainable development, and the Bayer brand stands for trust, reliability and quality

throughout the world. In fiscal 2018, the Group employed around 117,000 people and

had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, expenses to 5.2 billion euros. For more information, go to


© 2020 by Okulo Ltd.